Oriza, YuanMing Lead $15.5M Round In Ascentage Pharma
August 13, 2015 — 15:23 CST
This Data Is Locked!
This area is available only to Subscribers.
Shanghai-based cancer drug developer Ascentage Pharma Group Corporation has raised US$15.5 million in a new funding round led by Oriza Capital and YuanMing Capital, according... [DATA LOCKED]
UNLOCK DATA
Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals
